Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Generic Line > Watson Sues FDA Over Actos Generic Exclusivity as Competitors Launch

Generic Line

Aug. 29, 2012 | Vol. 29 No. 17

Watson Sues FDA Over Actos Generic Exclusivity as Competitors Launch

Watson Pharmaceuticals is suing the FDA after it failed to grant the company shared exclusivity on a generic of Type 2 diabetes drug Actos.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

FDA Questions Reckitt’s Motives in Petition Denial, OKs Suboxone ANDAs FDA Questions Reckitt Benckiser’s Motives in Petition Denial, OKs Two Suboxone Generics FDA: More Work May Be Needed to Discourage Anticompetitive Petitions Briefs

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.